Brief: Panbela Therapeutics To Receive Up To $9.5 Mln For Divestiture Of Assets Within Eflornithine (DFMO) Pediatric Neuroblastoma Program To Us WorldMeds
19/07/2023 13:15
July 19 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA THERAPEUTICS TO RECEIVE A TOTAL UP TO $9.5 MILLION
FOR
DIVESTITURE OF ASSETS WITHIN EFLORNITHINE (DFMO) PEDIATRIC
NEUROBLASTOMA PROGRAM TO US WORLDMEDS
* PANBELA THERAPEUTICS INC - DIVESTED CERTAIN ASSETS IN ITS
EFLORNITHINE PEDIATRIC NEUROBLASTOMA PROGRAM TO US WORLDMEDS
* PANBELA THERAPEUTICS-TO GET PAYMENTS ON USWM'S COMPLETION
OF
MILESTONES FOR EFLORNITHINE'S CLINICAL DEVELOPMENT, REGULATORY
APPROVAL, COMMERCIAL SALES
Source text for Eikon: ID:nGNX70q0G3
Further company coverage: PBLA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants